Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization

INTRODUCTION: Resurgence of pertussis, caused by Bordetella pertussis, necessitates novel vaccines and vaccination strategies to combat this disease. Alum-adjuvanted acellular pertussis vaccines (aPV) delivered intramuscularly reduce bacterial numbers in the lungs of immunized animals and humans, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yount, Kacy S., Hall, Jesse M., Caution, Kyle, Shamseldin, Mohamed M., Guo, Myra, Marion, Keirsten, Fullen, Audra R., Huang, Yimin, Maynard, Jennifer A., Quataert, Sally A., Deora, Rajendar, Dubey, Purnima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232778/
https://www.ncbi.nlm.nih.gov/pubmed/37275891
http://dx.doi.org/10.3389/fimmu.2023.1181876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232778/
https://www.ncbi.nlm.nih.gov/pubmed/37275891
http://dx.doi.org/10.3389/fimmu.2023.1181876

Ejemplares similares